BCR-ABL kinase domain mutations and clonal evolution as major causes of resistance to targeted therapy in chronic myelogenous leukemia

被引：0
|
作者：
Andrikovics, H.
Meggyesi, N.
Lueff, S.
Batai, A.
Adam, E.
Kozma, A.
Halm, G.
Nahajevszky, S.
Kapas, B.
Csukly, Z.
Lovas, N.
Remenyi, P.
Tordai, A.
Masszi, T.
机构：
[1] Natl Med Ctr, Dept Mol Diagnost, Budapest, Hungary
[2] Natl Med Ctr, Dept Hematol & Stem Transplantat, Budapest, Hungary
来源：
BLOOD REVIEWS | 2007年 / 21卷
关键词：
D O I：
10.1016/S0268-960X(07)70054-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [21] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [22] BCR-ABL Mutations in Chronic Myeloid Leukemia
    Ernst, Thomas
    La Rosee, Paul
    Mueller, Martin C.
    Hochhaus, Andreas
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (05) : 997 - +
  • [23] BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring
    Luu, Martin H.
    Press, Richard D.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (07) : 749 - 762
  • [24] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    Donato, NJ
    Wu, JY
    Stapley, J
    Lin, H
    Arlinghaus, R
    Aggarwal, B
    Shishodin, S
    Albitar, M
    Hayes, K
    Kantarjian, H
    Talpaz, M
    CANCER RESEARCH, 2004, 64 (02) : 672 - 677
  • [25] Resistance Profiling of BCR-ABL Compound Mutations Linked to Tyrosine Kinase Inhibitor Therapy Failure in Chronic Myeloid Leukemia
    Eide, Christopher A.
    Zabriskie, Matthew S.
    Adrian, Lauren T.
    Lange, Thoralf
    Deininger, Michael W.
    Druker, Brian J.
    O'Hare, Thomas
    BLOOD, 2011, 118 (21) : 616 - 616
  • [26] Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells
    J. L. Fernandez-Luna
    Apoptosis, 2000, 5 : 315 - 318
  • [27] Is another Bcr-Abl inhibitor needed for chronic myelogenous leukemia?
    Sausville, EA
    CLINICAL CANCER RESEARCH, 2003, 9 (04) : 1233 - 1234
  • [28] BCR-ABL in chronic myelogenous leukemia - How does it work?
    Goldman, John M.
    Melo, Junia V.
    ACTA HAEMATOLOGICA, 2008, 119 (04) : 212 - 217
  • [29] MOLECULAR CONSEQUENCES OF THE BCR-ABL TRANSLOCATION IN CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    LEUKEMIA & LYMPHOMA, 1993, 11 : 101 - 103
  • [30] Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells
    Fernandez-Luna, JL
    APOPTOSIS, 2000, 5 (04) : 315 - 318
12345